GSA Capital Partners LLP Has $1.45 Million Position in Amedisys Inc (NASDAQ:AMED)

Share on StockTwits

GSA Capital Partners LLP lowered its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 9.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,956 shares of the health services provider’s stock after selling 1,240 shares during the period. GSA Capital Partners LLP’s holdings in Amedisys were worth $1,452,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of AMED. Jennison Associates LLC raised its holdings in shares of Amedisys by 7.8% in the second quarter. Jennison Associates LLC now owns 9,307 shares of the health services provider’s stock valued at $1,130,000 after buying an additional 673 shares during the last quarter. Financial Enhancement Group LLC raised its holdings in shares of Amedisys by 17.8% in the second quarter. Financial Enhancement Group LLC now owns 855 shares of the health services provider’s stock valued at $104,000 after buying an additional 129 shares during the last quarter. Parkside Financial Bank & Trust bought a new position in shares of Amedisys in the second quarter valued at about $80,000. State Board of Administration of Florida Retirement System raised its holdings in shares of Amedisys by 9.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 18,080 shares of the health services provider’s stock valued at $2,195,000 after buying an additional 1,530 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new position in shares of Amedisys in the second quarter valued at about $35,359,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

NASDAQ:AMED traded down $2.75 on Friday, hitting $130.26. 231,773 shares of the stock were exchanged, compared to its average volume of 319,157. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.88 and a current ratio of 0.88. The stock has a market capitalization of $4.28 billion, a price-to-earnings ratio of 35.88, a P/E/G ratio of 1.99 and a beta of 1.42. The company’s 50-day moving average price is $130.39 and its 200 day moving average price is $123.79. Amedisys Inc has a 52 week low of $97.38 and a 52 week high of $141.98.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 31st. The health services provider reported $1.21 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.24. The company had revenue of $492.98 million during the quarter, compared to analysts’ expectations of $489.66 million. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. Amedisys’s revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.00 EPS. As a group, equities research analysts predict that Amedisys Inc will post 4.11 earnings per share for the current year.

AMED has been the subject of a number of research analyst reports. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. Raymond James lifted their price target on Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Monday, July 15th. Oppenheimer boosted their price objective on Amedisys from $140.00 to $150.00 in a report on Thursday, August 1st. Jefferies Financial Group set a $150.00 price objective on Amedisys and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, Barclays boosted their price objective on Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $135.90.

In other news, insider Sharon Brunecz sold 1,050 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $136.28, for a total value of $143,094.00. Following the completion of the sale, the insider now directly owns 11,480 shares of the company’s stock, valued at approximately $1,564,494.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David B. Pearce sold 4,228 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $131.30, for a total value of $555,136.40. Following the completion of the sale, the insider now directly owns 8,180 shares of the company’s stock, valued at $1,074,034. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,427 shares of company stock valued at $6,298,052. 2.90% of the stock is currently owned by company insiders.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: What Are Cryptocurrencies?

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Head-To-Head Review: Jerash Holdings   & Its Competitors
Head-To-Head Review: Jerash Holdings & Its Competitors
Analyzing Provectus Biopharmaceuticals  & Abbott Laboratories
Analyzing Provectus Biopharmaceuticals & Abbott Laboratories
Head to Head Comparison: Cyberark Software  vs. Red Violet
Head to Head Comparison: Cyberark Software vs. Red Violet
Ubiquiti  Cut to Hold at Zacks Investment Research
Ubiquiti Cut to Hold at Zacks Investment Research
Zacks Investment Research Lowers Stellus Capital Investment  to Sell
Zacks Investment Research Lowers Stellus Capital Investment to Sell
Playa Hotels & Resorts  Upgraded at Zacks Investment Research
Playa Hotels & Resorts Upgraded at Zacks Investment Research


 
© 2006-2019 Zolmax.